No data exist about the possibility that vertebral fracture in PMR patients could be independent of steroid therapy. For this reason, we aimed to investigate this topic by a case cohort study with a 1-year follow-up for each patient. We selected ten consecutive patients who experienced vertebral fractures (VF-group) during the Wrst month of 1-year follow-up period and without any other signiWcant associated condition. As a control group we studied ten control patients, without vertebral fractures and with a follow-up of 1 year, randomly selected among a larger group of patients aVected by polymyalgia rheumatica. The following data were analysed: eritrosedimention rate (ESR), visual analogical scale score (VAS), methyprednisolone daily dosage. Each patient had been monthly evaluated by the aforementioned clinical and laboratoristic parameters during the 1-year follow-up period. The VFgroup resulted with a higher and statistically signiWcant median corticosteroid 12-month total dosage [mean 3,480 mg (95%CI 2,805-3,030) vs. 2,760 mg (2,666.25-3,247.5)]. The VF-group had statistically signiWcant higher ESR and VAS AUC when compared to control group (median ESR AUC, 484.75 vs. 288.25; P = 0.0001; median VAS AUC, 70.75 vs. 43.5 P < 0.0001); ESR at the baseline (cut-oV >80 mm) showed a speciWcity of 90% (95%CI 56-100) and sensitivity of 70% (95%CI 35-93). VAS diVerence from Wrst to second month (cut-oV ·3) showed a speciWcity of 90% (95%CI 56-100) and sensitivity of 80% (95% CI 44-97). Our results point out that vertebral fracture might be predicted from commonly used laboratory (ESR) and clinical (VAS) Wndings.
Introduction
Polymyalgia Rheumatica (PMR) is an inXammatory condition of unknown cause that is characterized by an aching and morning stiVness in the shoulder and pelvic girdles other than the same kind of symptoms in the cervical region.
Well-documented data are available from literature about PMR and osteoporosis (1) (2) (3) . In particular, the beneWcial eVects of corticosteroid therapy in the treatment of PMR may be oVset by the occurrence of corticosteroidrelated osteoporosis. So, several studies have addressed the question of what dose of corticosteroids does not determine deleterious eVect on bone density: the results of these studies prove that this dose is uncertain (4) . On the other hand, in our knowledge, there are no data about both the frequency of vertebral fractures and related clinical features in recently diagnosed PMR patients. Moreover, no data For this reason, we aimed to investigate this last topic by a case cohort study with a 1-year follow-up for each polymyalgia rheumatica patient who had experienced a vertebral fracture within the Wrst month after the diagnosis.
Methods
We recruited ten consecutive patients who experienced vertebral fractures (VF-group) between during a previous 2-year period (2006-2007 years) aVected by Wrst diagnosed polymyalgia rheumatica, followed-up for 1 year, and without any other signiWcant associated condition. All the fractures were found out in acute symptomatic patients and had occurred during the Wrst month after the diagnosis. As a control group, we studied ten control patients, without vertebral fractures and with a follow-up of 1 year, randomly selected among a larger group of patients aVected by PMR. Randomization was performed by links in order to obtain a matched control group from some relevant variables (age, BMI, gender, comorbidities and drug therapy).
All the patients were referred to the Rheumatologic outpatient clinic of our Hospital trust, and all met the ACR criteria for diagnosis of PMR (5, 6). Moreover, in each patient of both groups PMR was diagnosed within 1 month from the onset of symptoms.
Each patient underwent an X-ray at baseline, after 12 months, and when experienced an acute pain along spine. The vertebral fractures were Wrst evaluated by X-ray after an acute aching episode and conWrmed by axial computerized tomography. We analysed the following data: eritrosedimention rate (ESR), visual analogical scale score (VAS) for pain assessment, methyprednisolone daily dosage. Each patient had been monthly evaluated by the aforementioned clinical and laboratoristic parameters during the 1-year follow-up period. The two groups did not meaningfully diVer for gender and age, neither there were meaningful diVerences for steroidal dosing, ESR, VAS at baseline. Moreover, the two groups did not diVer for percentage of patients overweight, hypertensive and diabetic (Table 1 ). There were no signiWcant diVerences about drug therapy (antidiabetic and antihypertensive) between the two groups.
Statistical analysis
The
) with change, prevalence (pretest likelihood), sensitivity, speciWcity and likelihood ratios with robust conWdence intervals were computed from ESR and VAS values for prediction of vertebral fractures. ROC plots and a ROC analysis were performed to individuate best sensitivity and speciWcity cut-oV points. A two-tailed alpha value of <0.05 was considered to be signiWcant.
Results
Study population variables at baseline are shown in Table 1 . Figures 1 and 2 show ESR and VAS trends of the VFgroup compared to the control one during 1-year follow-up.
Although the total amount of corticosteroids during the Wrst 3 months of observation was not signiWcantly diVerent between the two groups, the VF-group resulted with a higher and statistically signiWcant (P = 0.0135) median corticosteroid 12-month total dosage [3, 288.25; P = 0.0001; median VAS AUC, 70.75 vs. 43.5 P < 0.0001); ESR at the baseline (cut-oV >80 mm) showed a speciWcity of 90% (95%CI 56-100) and sensitivity of 70% (95%CI 35-93). VAS diVerence from Wrst to second month (cut-oV ·3) showed a speciWcity of 90% (95%CI 56-100) and sensitivity of 80% (95% CI 44-97).
Discussion
To our knowledge, this study is the Wrst that appraises the incidence of vertebral fractures after the clinical onset of the PMR. Our study deals with a case cohort study about 10 patients aVected by PMR with recent vertebral fractures (VF-group) compared to 10 patients aVected by PMR without vertebral fractures (NF-group). This is a pilot-study considered both the design and the sample size. However, this kind of design has allowed a strict selection of controls closely matched to the cases for meaningful variables.
So, conclusions of our study and related hypothesis could be suYciently strong to both elicit interest in scientiWc community on this topic and consequently draw sound clinical trials. Our results show that ESR was higher in VF-group in comparison with controls (P = 0.0403) at baseline. This Wnding suggests that subjects who will develop vertebral fractures precociously after the onset of PMR could belong to a subgroup of PMR subjects with a higher probability of vertebral fractures independent from steroid osteoporotic bone eVects.
In conclusion, our preliminary results point out that vertebral fractures both represent a problem for patients aVected by PMR, during the Wrst months after the onset of symptoms, and could be predicted from commonly used laboratory (ESR) and clinical (VAS) Wndings. Apart from the importance to investigate pathophysiological mechanisms, an eVort to understand the importance of our data and the needs for a precocious instrumental evaluation for osteoporosis, in this kind of patients, might be investigated in future studies for better utilizing economic resources. 
